The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s (J&J) atypical antipsychotic drug Risperdal (chemical name risperidone) for use in two types of treatment with children and adolescents. The approval was given yesterday, 22nd August. One application is for short treatment of schizophrenia in adolescents aged from 13 to 17 and the other is for short term treatment of manic or mixed episodes of bipolar I disorder in children aged between 10 and 17. Lithium has been the only FDA approved pediatric drug for treating schizophrenia and bipolar disorder in these age groups until now.
You Are What You Eat 